Electron IORT for Surgical Oncologists

Mobetron: Designed For The OR

For surgical oncologists, Mobetron serves a critical collaborative role in efficiently and effectively delivering an ablative dose of radiation directly to the tumor bed at the optimal biological time. It ensures confidence among surgical specialists that microscopic and residual cancers have been effectively treated.

Electron Beam IORT Affirmed by ASTRO

In its most recent APBI Consensus Statement, ASTRO offered “published evidence complemented by expert opinion” in distinguishing Mobetron from all other IORT treatment options available in the fight against breast cancer. In fact, electron IORT — as performed with the Mobetron— is the only single treatment radiation option for suitable patients affirmed by the ASTRO consensus.

The End of the Shielded OR

By enabling truly patient-specific treatment among surgeons and radiation oncologists, Mobetron improves efficiency by reducing treatment from weeks to minutes. And it gets entire surgical teams into the OR and up and running quickly. Faster treatment times mean fewer personnel are required and a greater number of patients may be treated. All of this equates to being able to focus on increased productivity and maximizing economics.

Time is critical and shorter treatment times deliver a host of benefits. But it doesn’t end there. Mobetron is also the tool that surgical teams can configure for their most efficient workflows. Mobetron’s thin-walled applicators provide virtually no dose to the skin and may be conformed to a variety of anatomical structures and tumor geometries. With field sizes ranging from 3 cm to 20 cm and treatment depths of up to 4 cm, Mobetron is simply the most flexible and powerful IORT device available.

AT A GLANCE: The Mobetron Case for Surgical Oncologists

Maximized Therapeutic Ratio:

Dose Uniformity and Configurability
Minimally Invasive
Improved Radiobiologic Effect: Single Fraction IORT has 2-3 times biologic impact of fractioned radiation therapy (Haddock, et, al 1999)

Optimized for the OR:

Multiple Variable Applicators
Precise Soft Docking Alignment
Single Sterile Environment

Proven Outcomes for Patients:

15,000 Patients Worldwide
Twenty Years of Clinical Data
Highly Conducive to Oncoplasty

Physician Success Stories

Dr. Julie Reiland

Dr. Julie Reiland, MD, Breast Surgeon — from Avera Regional Cancer Center — shares her passion and experience in treating patients and electron IORT with the Mobetron.

Claudine and Dr. Michele Carpenter

Claudine was in the right place after receiving a breast cancer diagnosis. Dr. Michele Carpenter, MD. and her team identified Claudine as a good candidate for Electron IORT Therapy with the Mobetron.

Dr. Mary Wilde

“In terms of why cosmetic outcome is superior, when we use Mobetron, we don’t have to radiate through the skin.” said Dr. Mary Wilde, MD. Dr. Wilde shares her experience in treating her breast cancer patients with IORT with the Mobetron.

It has to be the best. And that’s why we chose Mobetron. I really wanted something I could count on. That I really felt I could look my patients in the eye and tell them; ‘Yes, this is the best device' and there isn’t anybody that is going to get it better.”

Julie Reiland Smith, MD
Breast Surgeon, Avera Regional Cancer Center, Sioux Falls, South Dakota

Cancer Indications for Mobetron

Proven Cancer Indications:

Breast (Boost)
Breast (Single-Fraction APBI)
Pancreatic
Colorectal
Gynecological
Head and Neck
Sarcoma

Emerging Cancer Indications:

Brain
Esophageal
Gastric
Genitourinary
Lung
Pediatric
Prostate
Spinal Metastases

We now have doctors sending their patients to us from other communities because they recognize that Mobetron is a better treatment for their patients.”

Mary Wilde, MD
Surgical Oncologist, Scripps Memorial Hospital, California

What Makes Mobetron Different?

Why would more patients choose your cancer facility? Because your talent and technology are better than your competitors. Or put another way, you have something they want. Something that sets you apart. Our customers say it best: Mobetron is their differentiator. And the best oncologists want it as part of their arsenal in the fight against cancer. In fact, cancer centers that use Mobetron attract more qualified patients from a larger catchment area and the technology is a magnet for recruiting the world’s top oncological talent.

The Mobetron Demonstration

Let’s discuss how Mobetron will serve your surgical team and improve clinical efficacy in the OR.

CALL US :

(408) 636-1020

OR CONTACT US :

Sales Inquiry

Mobetron Overview

Learn how the Mobetron can be your differentiator in the OR.

Learn More

Clinical Research

Need proof? A history of clinical success tells the whole story.

See Clinical Research

Surgical Oncologists